Medical News

RSS

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

9 Mar 2010

Cornyn and Boehner sharpen criticism of Obama health proposal

"National Republican Senatorial Committee Chairman John Cornyn said Monday that if some type of health care legislation is able to limp its way out of Congress, GOP candidates across the country are poised to make it the premiere issue of the fall campaign," Politico reports. "While Cornyn said his personal preference would be to stop a bill entirely, his campaign committee is already preparing its attack line for a scenario that assumes Democrats squeeze a bill through the controversial reconciliation process in the next month."

9 Mar 2010

NIH awards Phase I SBIR grant to DNA Medicine Institute for emergency blood sensor

The DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced that it has been awarded a Phase I Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

9 Mar 2010

Aton Pharma introduces authorized generic version of Timoptic-XE

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.

9 Mar 2010

Abbott announces definitive agreement to acquire Facet Biotech

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

9 Mar 2010

Senate test vote today on bill to extend COBRA subsidy, doc fix and state Medicaid funding

The Senate is poised to consider a measure today that would include extending subsidies for COBRA benefits and unemployment insurance, prevent the Medicare payment cut for doctors and provide additional funding to state Medicaid programs.

9 Mar 2010

ACIST Medical Systems to provide CVi contrast injection system to HealthTrust Purchasing Group

ACIST Medical Systems, Inc., a world-leading provider of contrast-delivery systems for cardiology and radiology imaging, announced today that HealthTrust Purchasing Group, LP (HealthTrust), Brentwood, Tenn., one of the leading health care group purchasing organizations, has awarded the company a three-year contract, effective December 1, 2009, for ACIST cardiovascular injection technology, the ACIST | CVi® Contrast Delivery System.

9 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

Activity in lateral prefrontal cortex may improve emotion regulation in day-to-day life

Common wisdom tells us that for a successful relationship partners shouldn't go to bed angry. But new research from a psychologist at Harvard University suggests that brain activity-specifically in the region called the lateral prefrontal cortex-is a far better indicator of how someone will feel in the days following a fight with his or her partner.

9 Mar 2010

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

Allergan, Inc. today announced that the United States Food and Drug Administration has approved BOTOX® (onabotulinumtoxinA) for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity.

9 Mar 2010

Bioniche Pharma introduces Mefoxin in frozen premix bags

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the launch of Mefoxin® (cefoxitin injection) frozen premix bags. The launch marks the company's first product offering to be supplied in a frozen premix bag presentation. Mefoxin (cefoxitin injection) is manufactured by Baxter Healthcare Corporation using Baxter's proprietary GALAXY container technology.

9 Mar 2010

Health overhaul policy tidbits

NPR: For those who have forgotten what the Senate's bill would actually do as the debate has turned to politics and procedure, "a short refresher" may come in handy. The legislation's main concepts include the requirement that individuals buy health insurance, a plan that would help eliminate pre-existing condition exclusions and spread risk more widely, and subsidies to help people buy coverage to meet the new requirement (Rovner, 3/9).

9 Mar 2010

Carticept Medical completes $20M Series B financing round

Carticept Medical, Inc., a developer of innovative products for the treatment of cartilage injuries and osteoarthritis, today announced that it has completed a $20 million Series B financing round. New investor SonoSite, Inc. joined existing investors Domain Associates and New Enterprise Associates.

9 Mar 2010

Administration, health insurers point fingers at each other in premium hike dust-up

The Obama administration and insurance industry executives are continuing their battle over rate increases.

9 Mar 2010

VA streamlining Agent Orange claims process

USA Today: "The Department of Veterans Affairs plans to announce today that it will fully automate how it pays claims for illnesses related to exposure to the chemical Agent Orange to keep an overburdened system from collapse.

9 Mar 2010

Oldelft Benelux acquires distributorship for EOS imaging system

biospace med (www.biospacemed.com), an emerging medical technology company based in Paris, and Oldelft Benelux, a renowned specialist in medical diagnostic imaging, announced today the signature of an exclusive distribution agreement of EOS, the world’s first ultra-low-dose 2D|3D imager. The agreement will cover the distribution of EOS for the Benelux area (Belgium, The Netherlands & Luxembourg).

9 Mar 2010

ETEX receives FDA marketing clearance for CarriGen Porous Bone Substitute Material

ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.

9 Mar 2010

University of Michigan Health System evaluates factors that can reduce hospital deaths

Admission to a hospital when most of the beds are already full can be deadly for patients, according to a new University of Michigan Health System study showing high occupancy increases the risk of dying in the hospital by 5.6 percent.

9 Mar 2010

Americans for Tax Reform asks for clarification on applicability of 2.9% surtax on capital gains

Americans for Tax Reform today sent a letter to President Obama asking him to clarify whether or not the 2.9 percent surtax on "unearned income" applies to capital gains. If Obama's tax increase does fall on capital gains, the marginal tax rate on capital gains will eventually rise to 22.9 percent from today's level of 15 percent.

9 Mar 2010

Cantel Medical's fiscal 2010 second-quarter net income up 29%

CANTEL MEDICAL CORP. reported a 29% increase in net income to $4,876,000, or $0.29 per diluted share, on a 6.7% increase in sales to $66,587,000 for the second quarter ended January 31, 2010. This compares with net income of $3,774,000, or $0.23 per diluted share, on sales of $62,420,000 for the second quarter ended January 31, 2009.

9 Mar 2010

Medical News

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

Cornyn and Boehner sharpen criticism of Obama health proposal

NIH awards Phase I SBIR grant to DNA Medicine Institute for emergency blood sensor

Aton Pharma introduces authorized generic version of Timoptic-XE

Abbott announces definitive agreement to acquire Facet Biotech

Senate test vote today on bill to extend COBRA subsidy, doc fix and state Medicaid funding

ACIST Medical Systems to provide CVi contrast injection system to HealthTrust Purchasing Group

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Activity in lateral prefrontal cortex may improve emotion regulation in day-to-day life

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

Bioniche Pharma introduces Mefoxin in frozen premix bags

Health overhaul policy tidbits

Carticept Medical completes $20M Series B financing round

Administration, health insurers point fingers at each other in premium hike dust-up

VA streamlining Agent Orange claims process

Oldelft Benelux acquires distributorship for EOS imaging system

ETEX receives FDA marketing clearance for CarriGen Porous Bone Substitute Material

University of Michigan Health System evaluates factors that can reduce hospital deaths

Americans for Tax Reform asks for clarification on applicability of 2.9% surtax on capital gains

Cantel Medical's fiscal 2010 second-quarter net income up 29%

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News